DDD, let's not forget that in a 8K or 10K sometime in the last year, the company filed to withhold some piece of financial data from shareholders that could negatively effect something that was going on behind the scenes. At the time, we thought maybe it was negotiations with partnerships on trials, but it may have been reimbursement money from HE that they did not want to declare because they had not yet finished setting the price of DCVaxL in the US, and other countries. Yesterday's filings indicates that HE is still a viable thing and we've read antidotal info that would support the belief that some patients are taking advantage of DCVaxL through hospital exemption or compassionate care programs in Europe.
Market Data 
Markets 
AI
